Protocol · Pain Management
Opioid-Refractory Pain Management Support Protocol
Palmitoylethanolamide (PEA) and Alpha-Lipoic Acid are the core of this stack, with 5 supporting supplements. Each row gives the amount the protocol lists and the grade our evidence database holds for that supplement in Opioid-Refractory Pain Management Support.
We are re-verifying the studies cited on protocol pages; only confirmed citations are shown.
The stack
7 supplements · none graded yet
| Grade | Supplement | Amount listed | Why it’s in the stack | Evidence on file |
|---|---|---|---|---|
| Primary stackThe core of this protocol | ||||
| Palmitoylethanolamide (PEA) | Amount listed: 600–1,200 mg daily in divided doses | Endocannabinoid-like compound; anti-inflammatory; analgesic through multiple mechanisms | Not graded yet | |
| Alpha-Lipoic Acid | Amount listed: 600–1,200 mg daily | Antioxidant; effective for neuropathic pain; reduces nerve damage | Not graded yet | |
| Supporting stackListed as additions to the core | ||||
| Magnesium | Amount listed: 400–600 mg daily | NMDA receptor modulator; may reduce central sensitization; helps with muscle pain | Not graded yet | |
| Curcumin | Amount listed: 500–1,500 mg daily with enhanced absorption formulation | Anti-inflammatory; modulates multiple pain pathways; well-tolerated | Not graded yet | |
| Omega-3 Fatty Acids | Amount listed: 2–4 g EPA+DHA daily | Anti-inflammatory; reduces pro-inflammatory mediators; supports nerve health | Not graded yet | |
| Vitamin D | Amount listed: 2,000–4,000 IU daily (higher if deficient) | Deficiency common in chronic pain; correction may reduce pain levels | Not graded yet | |
| Boswellia | Amount listed: 300–500 mg standardized extract three times daily | Anti-inflammatory; inhibits 5-lipoxygenase; may help with various pain conditions | Not graded yet | |
How this protocol works
In plain language
Opioid-refractory pain refers to chronic pain that does not respond adequately to opioid medications, or where opioids cannot be used due to side effects, risks, or other factors. This is increasingly recognized as a distinct management challenge.
WHY PAIN MAY NOT RESPOND TO OPIOIDS:
- Opioid-induced hyperalgesia: Opioids themselves can increase pain sensitivity
- Central sensitization: Nervous system becomes hypersensitive
- Neuropathic pain: Nerve damage responds poorly to opioids
- Tolerance: Decreasing effectiveness over time
- Psychological factors: Depression, anxiety, catastrophizing
- Structural factors: Ongoing tissue damage
TYPES OF PAIN LESS RESPONSIVE TO OPIOIDS:
- Neuropathic pain (nerve damage)
- Central sensitization syndromes (fibromyalgia, CRPS)
- Cancer-related neuropathic pain
- Phantom limb pain
- Post-surgical chronic pain
MULTIMODAL APPROACH IS KEY:
Non-Opioid Medications:
- Antidepressants (duloxetine, amitriptyline)
- Anticonvulsants (gabapentin, pregabalin)
- NMDA antagonists (ketamine, memantine)
- Topical agents (lidocaine, capsaicin)
Interventional Options:
- Nerve blocks
- Spinal cord stimulation
- Intrathecal drug delivery
- Ablative procedures
Non-Pharmacological:
- Physical therapy
- Cognitive behavioral therapy for pain
- Acceptance and commitment therapy
- Mindfulness-based stress reduction
- Exercise
- Acupuncture
- TENS
PEA* is a well-studied alternative with good evidence for chronic pain.
Alpha-lipoic acid* is particularly helpful for neuropathic pain.
Magnesium* may help reduce central sensitization.
Expected timeline: Multimodal approaches require weeks to months to optimize. Supplements may provide additional modest benefit.